China Researchers Develop First Oral Vaccine Against Gastric Cancer
This article was originally published in PharmAsia News
Chinese scientists report creation of the first oral vaccine to guard against gastric cancer. The Ministry of Science and Technology said the vaccine blocks stomach bacteria believed linked to development of duodenal and gastric ulcers as well as stomach cancer. The bacteria involved is Helicobactor pylori, defeated by the vaccine so far through Phase III trials, earning it the China State FDA's "first-grade new medicine" status. The vaccine, which already has intellectual property rights protection, demonstrated a 72.1 percent protection rate against Hp bacteria. (Click here for more
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.